Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders

Linda Schönborn, Theodore E. Warkentin, Tim Chataway, Leonie Grosse, Paolo Simioni, Stephan Moll, Andreas Greinacher, Tom P. Gordon

Research output: Contribution to journalLetterpeer-review


Disorders caused by antibodies against platelet factor 4 (PF4) gained major attention during the pandemic, when platelet-activating anti-PF4 antibodies were found to explain vaccine-induced immune thrombocytopenia and thrombosis (VITT) after coronavirus disease 2019 (Covid-19) vaccination with two adenoviral vector–based vaccines, ChAdOx1 nCoV-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Johnson & Johnson–Janssen).1 Affected patients often have multiple or unusual sites of thromboses, such as the cerebral venous sinus and splanchnic veins, with high levels of d-dimer.2
Original languageEnglish
Pages (from-to)1827-1829
Number of pages3
JournalNew England Journal of Medicine
Issue number19
Publication statusPublished - 16 May 2024


  • Allergy/Immunology
  • Autoimmune Disease
  • Coagulation
  • Coronavirus
  • Hematology/Oncology
  • Infectious Disease
  • Vaccines
  • Viral Infections


Dive into the research topics of 'Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders'. Together they form a unique fingerprint.

Cite this